Urogen Pharma Ltd (NASDAQ:URGN) Expected to Post Earnings of -$1.20 Per Share

Brokerages expect Urogen Pharma Ltd (NASDAQ:URGN) to post ($1.20) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Urogen Pharma’s earnings, with the lowest EPS estimate coming in at ($1.33) and the highest estimate coming in at ($1.11). Urogen Pharma reported earnings per share of ($1.14) in the same quarter last year, which would suggest a negative year-over-year growth rate of 5.3%. The firm is scheduled to announce its next quarterly earnings results on Tuesday, August 13th.

According to Zacks, analysts expect that Urogen Pharma will report full year earnings of ($5.37) per share for the current year, with EPS estimates ranging from ($5.83) to ($4.82). For the next year, analysts anticipate that the business will post earnings of ($4.23) per share, with EPS estimates ranging from ($6.33) to ($1.66). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Urogen Pharma.

Urogen Pharma (NASDAQ:URGN) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($1.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.01. Urogen Pharma had a negative return on equity of 61.24% and a negative net margin of 4,296.08%.

URGN has been the subject of a number of recent analyst reports. Cowen reissued a “buy” rating on shares of Urogen Pharma in a research report on Monday, May 6th. Stifel Nicolaus reissued a “buy” rating and set a $63.00 price objective on shares of Urogen Pharma in a research report on Tuesday, March 5th. Raymond James set a $57.00 target price on Urogen Pharma and gave the company a “buy” rating in a report on Friday, March 1st. Oppenheimer restated a “buy” rating on shares of Urogen Pharma in a report on Tuesday, March 19th. Finally, HC Wainwright restated a “buy” rating and set a $75.00 target price on shares of Urogen Pharma in a report on Friday, March 1st. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Urogen Pharma presently has an average rating of “Buy” and an average target price of $59.50.

Shares of NASDAQ:URGN opened at $35.25 on Monday. The stock has a market cap of $504.63 million, a P/E ratio of -7.34 and a beta of 1.32. Urogen Pharma has a 12-month low of $33.37 and a 12-month high of $56.91.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Private Advisors LLC purchased a new position in shares of Urogen Pharma in the 1st quarter valued at about $329,000. FMR LLC lifted its stake in Urogen Pharma by 5.8% during the first quarter. FMR LLC now owns 588,203 shares of the company’s stock worth $21,728,000 after purchasing an additional 32,200 shares during the last quarter. Wildcat Capital Management LLC lifted its stake in Urogen Pharma by 27.2% during the first quarter. Wildcat Capital Management LLC now owns 779,003 shares of the company’s stock worth $28,776,000 after purchasing an additional 166,509 shares during the last quarter. Morgan Stanley lifted its stake in Urogen Pharma by 65.4% during the first quarter. Morgan Stanley now owns 24,923 shares of the company’s stock worth $920,000 after purchasing an additional 9,856 shares during the last quarter. Finally, Man Group plc lifted its stake in Urogen Pharma by 49.5% during the first quarter. Man Group plc now owns 178,996 shares of the company’s stock worth $6,612,000 after purchasing an additional 59,260 shares during the last quarter. Institutional investors and hedge funds own 97.86% of the company’s stock.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The company's lead product candidates, UGN-101 and UGN-102 are proprietary formulations of the chemotherapy drug mitomycin, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.

Recommended Story: What does a bar chart mean for investors?

Get a free copy of the Zacks research report on Urogen Pharma (URGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Urogen Pharma (NASDAQ:URGN)

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.